
Ayvakit is safe long-term treatment for systemic mastocytosis
New results show Ayvakit (avapritinib) is an effective and safe long-term treatment for systemic mastocytosis (SM). The data, announced by Sanofi company Blueprint Medicines, showed Ayvakit led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in… Read More

